More on Sangamo Biosciences (SGMO): Q4 beats on both top and bottom line as higher revenues were...

|About: Sangamo Therapeutics, Inc. (SGMO)|By:, SA News Editor

More on Sangamo Biosciences (SGMO): Q4 beats on both top and bottom line as higher revenues were generated from the Company's collaboration agreements with Shire (SHPG), Dow AgroSciences (DAS) and Sigma-Aldrich Corporation (SIAL), plus additional research grants. The company guides FY2013 revenue slightly to the lower side of estimates, now expecting to earn between $20M -24M, versus the consensus of $23.09M. Shares -1% AH.